Federal Trade Commission Chairwoman Edith Ramirez told senators Tuesday that the Supreme Court decision authorizing the FDA to sue drugmakers for patent settlements should discourage some of the most outrageous deals and let regulators fight others better. Diane Bieri spoke on behalf of PhRMA and said drugmakers spend 10 to 15 years and $1 billion to bring innovative drugs to the market, and patent settlements can bring generics to market before patent expiry.

Full Story:

Related Summaries